ReviewBMC microbiology2023
Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections.
Review in BMC microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Antibiotic Nanoparticles-Loaded Wound Dressings AgainstInternational journal of nanomedicine · 2024Pooled it
- Bacteriocins as Alternative Antimicrobial Agents for Wound-Associated Infections: Mechanisms, Activity Against Biofilms and Translational Potential.Antibiotics (Basel, Switzerland) · 2026Review
- Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa.Infection · 2026Review
- Fluorophenylalanine-Containing Dipeptides with Antibiofilm Activity AgainstMolecules (Basel, Switzerland) · 2026Article
- In Silico Mutational Analysis of Two-Component System Genes Associated with Colistin Resistance in ClinicalBiomolecules · 2026Article
- Remodeling the pathological airway: advanced nanotechnology for diagnostics and therapeutics in cystic fibrosis.Journal of nanobiotechnology · 2026Review
- Antimicrobial Resistance of ESKAPE Pathogens Identified in Patients with Necrotizing Fasciitis: A 10-Year Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- A Fluorescent Aptasensor Based on Tb-MOFs and Its Application for the Detection ofFoods (Basel, Switzerland) · 2026Article
- Mutations in the mucA gene of Pseudomonas aeruginosa promote disease exacerbation.Archives of microbiology · 2026Review
- Mechanisms ofMedicina (Kaunas, Lithuania) · 2026Review
- Newly isolatedFrontiers in microbiology · 2026Article
- Rational Targeting and gRNA Design for Enhancing Quorum Quenching inComputational and structural biotechnology journal · 2026Article
- Article
- Molecular Framework of Multidrug Resistance in Pseudomonas aeruginosa.Current microbiology · 2025Review
- Algal metabolites as emerging anti-virulence therapeutics against Pseudomonas aeruginosa.Archives of microbiology · 2025Review
- Effect of supplementation on biofilms and antibiotic efficacy againstIranian journal of microbiology · 2025Review
- Identification of potential anti-biofilm agents targeting LasR in Pseudomonas aeruginosa through machine learning-driven screening, molecular docking, and dynamics simulations.Scientific reports · 2025Article
- From the Reclaimed Water Treatment Plant to Irrigation in Intensive Agriculture Farms: Assessment of the Fate of Antibiotics, Antibiotic Resistance Bacteria and Genes, and Microbial Pathogens at Real Scale.Environmental science & technology · 2025Article
- In silico analysis of hypothetical proteins in Pseudomonas aeruginosa PAC1: Structural and functional insights.Journal, genetic engineering & biotechnology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The opportunistic human pathogen Pseudomonas aeruginosa is the causal agent of a wide variety of infections. This non-fermentative Gram-negative bacillus can colonize zones where the skin barrier is weakened, such as wounds or burns. It also causes infections of the urinary tract, respiratory system or bloodstream. P. aeruginosa infections are common in hospitalized patients for which multidrug-resistant, respectively extensively drug-resistant isolates can be a strong contributor to a high rate of in-hospital mortality. Moreover, chronic respiratory system infections of cystic fibrosis patients are especially concerning, since very tedious to treat. P. aeruginosa exploits diverse cell-associated and secreted virulence factors, which play essential roles in its pathogenesis. Those factors encompass carbohydrate-binding proteins, quorum sensing that monitor the production of extracellular products, genes conferring extensive drug resistance, and a secretion system to deliver effectors to kill competitors or subvert host essential functions. In this article, we highlight recent advances in the understanding of P. aeruginosa pathogenicity and virulence as well as efforts for the identification of new drug targets and the development of new therapeutic strategies against P. aeruginosa infections. These recent advances provide innovative and promising strategies to circumvent infection caused by this important human pathogen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.